UNSPSC 51332822: Perphenazine

This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FTA7XXY4EZ, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but generally known as perphenazine, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Perphenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG.

UNSPSC 51332822 Perphenazine is a Commodity code that nominally identifies a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code does not reflect purchases of perphenazine itself. Instead, the code appears in solicitations for broader pharmaceutical procurement programs, including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products distributed through state health agencies and cooperative purchasing alliances. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and cooperative purchasing organizations serving multiple state jurisdictions. The work being solicited is the supply and delivery of pharmaceutical products—both branded and generic—and related healthcare commodities to support community health initiatives, employee health plans, and facility-based healthcare programs.

Geographic spread of recent activity centers on Florida and the Upper Midwest and Southwest. The Seminole County, Florida IFB for naloxone and drug deactivation systems (due July 26, 2023) represents direct county health procurement; the Texas Health and Human Services Commission's April 2026 RFI on direct-to-manufacturer prescriptions signals state-level interest in restructuring pharmacy benefit procurement; and the Minnesota Multistate Cooperative Purchasing Alliance's March 2026 RFP for generic pharmaceuticals and OTC products, administered by Minnesota's Department of Administration and serving participating jurisdictions including Oregon, demonstrates cooperative-vehicle activity at scale. The MMCAP solicitation, with responses due March 26, 2026, requires vendors to work through three authorized wholesalers and specifies pricing evaluation weighted 75 percent toward price competitiveness, with contract terms of two years for new vendors and compliance with cGMP and Drug Supply Chain Security Act standards. The code shows fragmented recent activity across multiple procurement models—direct purchase, market research, and cooperative contracting—rather than concentrated demand for the specific pharmaceutical named in the code.